Approximately 3 to 5% of @entity1 with @entity1072 ( @entity1072 ) develop an aggressive large cell @entity1893 (NHL) known as @entity6492 ( @entity6492 ). @entity6492 has a poor prognosis and a response rate of < 10% with @entity3118 -based or other cytotoxic combination regimens. The aim of this study was to evaluate the efficacy and @entity137 of the hyperCVXD regimen in @entity6492 . Twenty-nine @entity1 , median age 61 years (36-75) 23 males, were treated. Prior diagnosis was @entity1072 in 26 @entity1 , @entity1893 in 2, and @entity6491 in 1. Treatment consisted of fractionated @entity786 , @entity1891 , daunoXome and @entity619 . Six @entity1 (20%) died while receiving study therapy, 4 (14%) during the first cycle of whom 2 had started therapy with overt @entity55 . Grade 4 @entity3028 occurred in all 95 cycles of therapy with a median time to recovery of 14 days. Twenty three (24%) cycles were complicated by fever, and 15 (15%) by @entity55 . @entity295 was documented in 8 (8%) cycles, and @entity16 in 5 (5%) of cycles. Twenty three @entity1 had a platelet count < 100 x 10(9)/l prior to therapy: a greater than 50% decrease in platelet count over pre-therapy level occurred in 79% of first cycles, overt @entity548 occurred in 4 (4%) of all cycles. Eleven of 29 (38%) @entity1 achieved complete remission (CR), 4 of whom have relapsed after 5, 6, 9, and 12 months of remission. Two of 11 CR @entity1 presented with @entity6492 without any prior @entity1072 therapy. One @entity1 had a partial remission. Thus the overall response rate was 12/29 (41%). Overall median survival was 10 months, 19 months in @entity1 who achieved CR, 3 months in those who did not (p = 0.0008). A landmark analysis performed at 2 months from start of therapy comparing @entity1 alive in CR versus @entity1 alive but not in CR showed a median survival of 19 months versus 6 months, respectively (p 0.0017). In conclusion the hyper CVXD regimen has a relatively high response rate, significant @entity137 and a moderate impact on survival in @entity6492 .

Fractionated @entity786 , @entity1891 , liposomal daunorubicin (daunoXome), and XXXX (hyperCVXD) regimen in @entity6492 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity295 :: ('MESH:D018805', 'Disease') :: ['Sepsis'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia'] @entity6491 :: ('MESH:D015463', 'Disease') :: ['Prolymphocytic leukemia'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity6492 :: ('MESH:C537025', 'Disease') :: ['RS', "Richter's syndrome"] @entity1893 :: ('MESH:D008228', 'Disease') :: ['NHL', "non Hodgkin's lymphoma"] @entity3028 :: ('MESH:D000380', 'Disease') :: ['granulocytopenia']
@entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']
